Compare HER2 inhibitors. View important safety information, ratings, user reviews, popularity and more.

Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.

Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years. Keywords: HER2 inhibitors, cancer, antibodies, tyrosine kinase inhibitors, antibody-drug conjugates 1.

Jul 18, 2023 · Key takeaways: There are several human epidermal growth factor receptor 2 (HER2) inhibitors that treat HER2-positive breast cancer. Herceptin (trastuzumab), Perjeta (pertuzumab), and Tykerb (lapatinib) are just a few.

Feb 4, 2024 · An increasing number of HER2-targeted drugs including specific monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs) have been approved by the U.S. Food and Drug Administration.

Oct 22, 2024 · Kinase inhibitors block the action of HER2 and other kinase proteins that help cancer cells grow. Neratinib (Nerlynx) is a kinase inhibitor used to treat HER2-positive early breast cancer...

Nov 7, 2022 · Innovations in pathology, molecular biology and drug development have enabled HER2-positive breast cancer (BC), a historically aggressive subtype, to become one with impressive outcomes.

May 20, 2021 · Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years,...

HER2 mutations have been found in non-small-cell lung cancers (NSCLC) and can direct treatment.

Oct 12, 2023 · Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.